SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EPRATUZUMAB IN JAPANESE PATIENTS WITH MODERATE-TO-SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A PHASE 1/2 STUDY

被引：1
|
作者：
Yamamoto, J. [1 ]
Lledo-Garcia, R. [2 ]
Tsuru, T. [3 ]
Tanaka, Y. [4 ]
Koike, T. [5 ]
机构：
[1] UCB Pharma, Tokyo, Japan
[2] UCB Pharma, Slough, Berks, England
[3] Med Co LTA, PS Clin, Fukuoka, Japan
[4] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka 807, Japan
[5] NTT Sapporo Med Ctr, Sapporo, Hokkaido, Japan
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷
关键词：
D O I：
10.1136/annrheumdis-2014-eular.1754
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0383
引用
收藏
页码：526 / 526
页数：1
相关论文
共 50 条
  • [1] Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study
    Tsuru, Tomomi
    Tanaka, Yoshiya
    Kishimoto, Mitsumasa
    Saito, Kazuyoshi
    Yoshizawa, Seiji
    Takasaki, Yoshinari
    Miyamura, Tomoya
    Niiro, Hiroaki
    Morimoto, Shinji
    Yamamoto, Junichi
    Lledo-Garcia, Rocio
    Shao, Jing
    Tatematsu, Shuichiro
    Togo, Osamu
    Koike, Takao
    [J]. MODERN RHEUMATOLOGY, 2016, 26 (01) : 87 - 93
  • [2] EPRATUZUMAB DEMONSTRATES CLINICALLY MEANINGFUL IMPROVEMENTS IN PATIENTS WITH MODERATE-TO-SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM EMBLEM™, A PHASE IIB STUDY
    Gordon, Caroline
    Kalunian, K.
    Petri, M.
    Strand, V.
    Kilgallen, B.
    Barry, A.
    Wallace, D.
    [J]. RHEUMATOLOGY, 2012, 51 : 25 - 25
  • [3] Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized, Placebo-Controlled Trials
    Clowse, Megan E. B.
    Wallace, Daniel J.
    Furie, Richard
    Petri, Michelle
    Pike, Marilyn
    Leszczynski, Piotr
    Neuwelt, C. Michael
    Hobbs, Kathryn
    Keiserman, Mauro
    Duca, Liliana
    Kalunian, Kenneth
    Bongardt, Sabine
    Stach, Christian
    Beaudot, Carolyn
    Kilgallen, Brian
    Galateanu, Catrinel
    Gordon, Caroline
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [4] Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus
    Yamada, Masanori
    Akita, Mikio
    Nakagawa, Tomofumi
    Takahashi, Naoki
    Endo, Akira
    Yoshida, Pascal
    [J]. JOURNAL OF DRUG ASSESSMENT, 2013, 2 (01) : 40 - 48
  • [5] Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to-Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study
    Wallace, D. J.
    Hobbs, K.
    Clowse, M. E. B.
    Petri, M.
    Strand, V.
    Pike, M.
    Merrill, J. T.
    Leszczynski, P.
    Neuwelt, C. M.
    Jeka, S.
    Houssiau, F.
    Keiserman, M.
    Ordi-Ros, J.
    Bongardt, S.
    Kilgallen, B.
    Galateanu, C.
    Kalunian, K.
    Furie, R.
    Gordon, C.
    [J]. ARTHRITIS CARE & RESEARCH, 2016, 68 (04) : 534 - 543
  • [6] Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus
    Chia, Yen Lin
    Tummala, Raj
    Mai, Tu H.
    Rouse, Tomas
    Streicher, Katie
    White, Wendy, I
    Morand, Eric F.
    Furie, Richard A.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (09): : 1094 - 1105
  • [7] Evaluation of the Efficacy and Safety of Anifrolumab in Moderate-to-Severe Systemic Lupus Erythematosus
    Cingireddy, Ananya Reddy
    Ramini, Navya
    Cingireddy, Anirudh Reddy
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
  • [8] Epratuzumab Maintains Improvements In Disease Activity For Over 2 Years In Patients With Moderate-To-Severe Systemic Lupus Erythematosus: Results From An Open-Label Long-Term Extension Study
    Clowse, Megan E. B.
    Houssiau, Frederic
    Petri, Michelle A.
    Kilgallen, Brian
    Kalunian, Kenneth
    Strand, Vibeke
    Bongardt, Sabine
    Gordon, Caroline
    Wallace, Daniel J.
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S737 - S738
  • [9] TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE SEVERITY
    Strand, V.
    Johnson, J.
    Vandeloo, C.
    Galateanu, C.
    Lobosco, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 1171 - 1171
  • [10] Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
    Wallace, Daniel J.
    Kalunian, Kenneth
    Petri, Michelle A.
    Strand, Vibeke
    Houssiau, Frederic A.
    Pike, Marilyn
    Kilgallen, Brian
    Bongardt, Sabine
    Barry, Anna
    Kelley, Lexy
    Gordon, Caroline
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) : 183 - 190
12345